Funding for this research was provided by:
Region Skåne, Sweden
Scandinavian Society for Antimicrobial Therapy
Probi AB, Lund, Sweden
Received: 13 May 2018
Accepted: 25 September 2018
First Online: 28 October 2018
Ethics approval and consent to participate
: The original study was approved by the Human Ethics Committee of Lund University (LU 346–03), and the Local Ethical Review Board, Lund Sweden, which has replaced the former committee, approved the amendment for the present expansion. Informed consent was obtained from the patients or their next of kin.
: Not applicable. All results are presented on a group basis.
: Probi AB provided the study product and performed bacterial analyses as an unconditional grant. Probi AB has also done the same in earlier studies conducted by BK. Probi AB holds the patent for the investigated bacterium, but there is no patent regarding the studied application.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.